Convenient and Effective Treatment Monitoring.

Serial measurement of iCTCs in routinely collected patient blood samples during the course of treatment and beyond can monitor for effective response, relapse to allow a timely change of a failing therapy, or to reinitiate therapy following recurrence.

• Although almost 80% of ovarian cancer patients respond to standard chemotherapy, half of them recur within one year. Similar recurrence rates occur in lung and pancreatic cancer.
• However, current CT imaging and serum CA125 methods detect recurrence too late to be effectively treatable. There is also a lack of methods for selecting from the 30+ therapies available.
• Applied DNA developed unique invasive circulating tumor cell (iCTC) technology to enrich iCTCs from blood for both early diagnosis of recurrence and therapy selection.
• iCTC™ assays were able to detect recurrences of ovarian cancer ~six months before conventional CT imaging and serum CA125 found evidence of recurrence.

Surveillance screening of ovarian cancer recurrence with CT imaging, serum CA125, and iCTCs.

Citation: Pearl, ML 2014; 2015 Gyn. Oncol.